Principal Financial Group
ACRS icon

Principal Financial Group’s Aclaris Therapeutics ACRS Stock Holding History

Principal Financial Group’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-17,654
Closed -$21.9K – 2365
2024
Q1 		$21.9K Sell
17,654
-1,765
-9% -$2.1K ﹤0.01% 2401
2023
Q4 		$20.4K Buy
19,419
+654
+3% +$2K ﹤0.01% 2384
2023
Q3 		$129K Sell
18,765
-368
-2% -$3.15K ﹤0.01% 2242
2023
Q2 		$198K Buy
19,133
+2,200
+13% +$19.9K ﹤0.01% 2186
2023
Q1 		$137K Sell
16,933
-1,275
-7% -$16.2K ﹤0.01% 2243
2022
Q4 		$287K Buy
18,208
+1,811
+11% +$29.1K ﹤0.01% 2112
2022
Q3 		$259K Buy
16,397
+240
+1% +$3.78K ﹤0.01% 2128
2022
Q2 		$226K Sell
16,157
-16,096
-50% -$226K ﹤0.01% 2263
2022
Q1 		$556K Sell
32,253
-13,152
-29% -$179K ﹤0.01% 2092
2021
Q4 		$660K Sell
45,405
-7,590
-14% -$115K ﹤0.01% 2065
2021
Q3 		$954K Buy
52,995
+8,799
+20% +$141K ﹤0.01% 2015
2021
Q2 		$776K Buy
+44,196
New +$1M ﹤0.01% 2105

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Principal Financial Group's ACRS Position: Q2 2024 in Review

Principal Financial Group sold out of Aclaris Therapeutics (ACRS) in Q2 2024, closing a stake of 17,654 shares — an estimated $21.9K sold.

Principal Financial Group first reported a position in ACRS in Q2 2021 and held it in 12 quarters. The position peaked at $954K in Q3 2021. 98 funds tracked by Wall St. Rank hold ACRS as of Q2 2024.

  • Principal Financial Group reported no remaining Aclaris Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Principal Financial Group sold 17,654 Aclaris Therapeutics shares in Q2 2024, an estimated $21.9K.
  • Principal Financial Group first reported a position in Aclaris Therapeutics in Q2 2021 and held it in 12 quarters.
  • Principal Financial Group's Aclaris Therapeutics position peaked at $954K in Q3 2021.
  • 98 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2024.

Based on Principal Financial Group's 13F filing for Q2 2024, filed 29 Jul 2024.